A detailed history of Meridian Financial, LLC transactions in Cytokinetics Inc stock. As of the latest transaction made, Meridian Financial, LLC holds 4,318 shares of CYTK stock, worth $250,357. This represents 0.15% of its overall portfolio holdings.

Number of Shares
4,318
Previous 4,318 -0.0%
Holding current value
$250,357
Previous $234 Million 2.55%
% of portfolio
0.15%
Previous 0.17%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$47.86 - $75.05 $38,288 - $60,040
-800 Reduced 15.63%
4,318 $234 Million
Q1 2024

Aug 13, 2024

SELL
$63.75 - $108.06 $56,227 - $95,308
-882 Reduced 14.7%
5,118 $359 Million
Q4 2023

Aug 13, 2024

BUY
$26.88 - $83.49 $161,280 - $500,939
6,000 New
6,000 $501 Million
Q3 2023

Aug 13, 2024

SELL
$29.46 - $36.61 $223,630 - $277,906
-7,591 Closed
0 $0
Q1 2023

Aug 13, 2024

BUY
$33.36 - $45.71 $253,235 - $346,984
7,591 New
7,591 $267 Million

Others Institutions Holding CYTK

About CYTOKINETICS INC


  • Ticker CYTK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 94,144,096
  • Market Cap $5.46B
  • Description
  • Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...
More about CYTK
Track This Portfolio

Track Meridian Financial, LLC Portfolio

Follow Meridian Financial, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Meridian Financial, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Meridian Financial, LLC with notifications on news.